Zura Bio Ltd (ZURA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$4.46

From 52W high−36.65%

Volume1.66M

Market cap$427.40M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$4.46

From 52W high

−36.65%

Volume

1.66M

Market cap

$427.40M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.6x

P/E (TTM)

—

RSI (14)

30.1

MomentumView details →

1D Return

−2.41%

YTD Return

−14.79%

SummaryUpdated Jun 1, 2026

Zura Bio Limited (NASDAQ:ZURA) is a clinical-stage biotechnology company founded and based in San Diego, California. The company went public in March 2023 and focuses on developing novel therapeutic medicines to treat immune and inflammatory disorders. As a pre-revenue biotechnology firm, Zura Bio is currently advancing multiple drug candidates through clinical trials, with its lead programs targeting specific biological pathways involved in autoimmune and inflammatory diseases.

Ask drillr about Zura Bio Ltd →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−43.51%

ROA (TTM)

−40.18%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−48.68%

FCF YoY

−77.68%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−76.67%

EBITDA YoY

−29.26%

MomentumView details →

1D Return

−2.41%

YTD Return

−14.79%

1Y Return

+124.37%

RSI (14)

30.1

vs 50D SMA

−19.24%

vs 200D SMA

−15.81%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

12.90x

Quick Ratio

12.90x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.21

EPS Surprise

−9.78%

Beats (12Q)

3/12

Next Q EPS Est

−$0.21

Avg Surprise (4Q)

−55.48%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−85.74M

Op. CF (TTM)

−77.55M

Next earningsNov 12, 2026 →

Latest newsMore news →

Zura Bio Limited announced its financial results for the second quarter ended June 30, 2026, and provided corporate updates.40d ago

Similar companies

Atea Pharmaceuticals, Inc.AVIR Uni-Bio Science Group Limited00690.HK Opus Genetics, Inc.IRD PureTech Health plcPRTC Cabaletta Bio, Inc.CABA Artiva Biotherapeutics, Inc.ARTV Find similar companies →

Latest newsMore news →

Zura Bio Limited granted inducement stock options to purchase up to 587,000 Class A Ordinary Shares to thirteen newly hired employees on August 20, 2026, as inducements material to their employment.30d ago Zura Bio Limited announced its financial results for the second quarter ended June 30, 2026, and provided corporate updates.40d ago